1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
695CF48928EF0C0E0002586010031507D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-use-of-digital-technologies-within-medical-affairs-use-of-artificial-intelligence?opendocument
18
19opendocument
2018.213.192.104
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Digital Technology Cross-Functional Digital Transformation

Best Practices in the Use of Digital Technologies within Medical Affairs: Use of Artificial Intelligence in Medical Affairs

ID: 5645


Features:

8 Info Graphics

26 Data Graphics

840+ Metrics


Pages/Slides: 42


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in the use of Digital Technologies within Medical Affairs: Use of Artificial Intelligence in Medical Affairs”

STUDY OVERVIEW

As biopharma organizations increasingly turn to digital tools to shape Medical Affairs’ interactions with key stakeholders, they need to ensure they are also expanding the use of Artificial Intelligence to support their digital initiatives.

Best Practices, LLC conducted this benchmarking research to probe the use of digital technologies within Medical Affairs. The study provides benchmarks around the use and value of utilizing AI for digital initiatives in Medical Affairs.

Insights in this study are further presented into three different segments: Digital Leaders; Digital Majority; and Digital Laggards.

KEY TOPICS

  • Digital Initiative Overview and Key Findings
  • Artificial Intelligence in Medical Affairs

KEY METRICS
  • Use of artificial intelligence in Medical Affairs – Total benchmark class
  • Internal vs external impact of artificial intelligence in Medical Affairs – Total benchmark class
  • Active use of artificial intelligence by Medical Affairs in utilizing internal/ external data sources
  • Active use of artificial intelligence by Medical Affairs in facilitating medical activities
  • Internal vs external impact of artificial intelligence in Medical Affairs – Digital leaders, Digital Majority and Digital Laggards
  • Development of artificial intelligence tools for medical organization – Total benchmark class
  • Development of artificial intelligence tools for medical organization – Digital leaders vs. digital majority vs. digital laggards
  • Development of artificial intelligence – Functions / units or centers of excellence involved; collaboration with specific functions / units or centers of excellence; collaboration with multiple functions; external partners / vendors involved
  • Usage of artificial intelligence tools and analytics by Medical Affairs - Total benchmark class
  • Usage of artificial intelligence tools and analytics by Medical Affairs - Digital leaders vs. digital majority vs. digital laggards
  • Factors responsible for successful AI based external partnerships/vendor relationships – Total benchmark class
  • Factors responsible for successful AI based external partnerships/vendor relationships – Digital leaders vs. digital majority vs. digital laggards
SAMPLE KEY FINDINGS
  • Digital Leaders: Medical’s biggest use of AI related to internal/external data sources is to understand patient experience (73%)

METHODOLOGY

Best Practices, LLC engaged 74 executives from 53 leading life sciences companies in this research through a benchmarking survey instrument and interviews. The study insights are mostly from directors and higher management executives, representing nearly 80% of the participants. Insights in this research are presented into three different segments to provide deeper insights: Digital Leaders (16 respondents); Digital Majority (38 respondents); and Digital Laggards (20 respondents).


Industries Profiled:
Biotech; Medical Device; Pharmaceutical; Biopharmaceutical; Diagnostic; Health Care; Chemical; Manufacturing; Communications; Clinical Research; Laboratories; Science; Consulting


Companies Profiled:
Aeglea BioTherapeutics; Alcon; Alexion Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Astellas; AstraZeneca; BioDelivery Sciences International; Inc.; Biodesix; bioMerieux; Boehringer Ingelheim; Eisai; Eli Lilly and Company; EMD Serono; Exelixis ; GE Healthcare; Genentech; GRAIL; Grifols; GlaxoSmithKline ; Ipsen; Janssen; Jazz Pharmaceuticals; Julphar; Kedrion Biopharma; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; MyoKardia; Nabriva Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; Radius Health; Reata Pharmaceuticals; Roche; Sage Therapeutics; Sandoz; Sanofi; Sanofi Genzyme; Santen; Springworks Therapeutics; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; Thermo Fisher Scientific; UCB Pharma; Vertex Pharmaceuticals; Vynamic

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.